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Diffusion-weighted MRI (DW-MRI) is becoming increasingly important in the assessment and 
characterisation of malignant tumours in the prostate1. However most DW-MRI studies use only 
the apparent diffusion coefficient (ADC) for cancer assessment, which lacks specificity and fails 
to associate contrast changes to particular microstructure features. Model-based quantitative 
imaging techniques can ameliorate problems associated with simplistic diffusion-based indices. 
One such example is VERDICT MRI2, a model-based DW-MRI technique that has been used to 
estimate microstructural differences between prostate tumours and normal tissue2,3. The aim of 
this study is to evaluate the VERDICT method in combination with an ultrafast fitting algorithm 
called AMICO4 for microstructural prostate tissue characterisation in a test-retest experiment. 
Six subjects underwent VERDICT DW-MRI using a 3T scanner (b-values range 90-3000 s/mm)5. 
The scan was repeated after a 2-minute interval. The VERDICT model was fitted to the data with 
the AMICO framework4 and microstructural parameter maps were computed. For each subject a 
board certified radiologist (EJ) contoured two regions of interest in the VERDICT fIC 
(Intracellular fraction) map: a region corresponding to a cancerous lesion and a region for normal 
tissue on the same slice and their median values were calculated. Bland-Altman plots were used 
to analyse the agreement between the maps from the 
two different acquisitions. The rest of the VERDICT 
parametric maps (fIC, fEES - extracellular 
extravascular fraction and cellularity) were also 
computed. All the VERDICT maps were repeatable 
and maximised lesion conspicuity. Quantitatively, 
Pearson r2 coefficients for the 3 maps were 0.929, 
0.934, 0.896, respectively. See figure for fIC maps for 
both acquisitions (one patient) and the corresponding 
Bland-Altman plots. 
To conclude, VERDICT MRI can characterise 
microstructural differences between lesion and normal 
prostate tissue in a clinically practical time and a 
repeatable manner. This represents a significant step 
towards technical validation of the VERDICT estimates as imaging biomarkers. The method 
should be further evaluated in larger cohorts and the imaging parameters should be 
histologically validated. 
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